What development phase is EDROPHONIUM CHLORIDE in?

EDROPHONIUM CHLORIDE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

EDROPHONIUM CHLORIDE

FDA-approved approved Small molecule Quality 0/100

Edrophonium chloride is a marketed drug with a key composition patent expiring in 2028. Its primary strength lies in its established market presence and long-standing use. The primary risk is the potential increase in competition following the patent expiry in 2028.

At a glance

Generic name	EDROPHONIUM CHLORIDE
Modality	Small molecule
Phase	FDA-approved
First approval	1951

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

The Pathophysiology of Orthostatic Hypotension (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
FDA label	Mechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

EDROPHONIUM CHLORIDE CI brief — competitive landscape report
EDROPHONIUM CHLORIDE updates RSS · CI watch RSS